Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis

Main Article Content

Eric Simpson
Oregon Health & Science University, Portland, USA

Gil Yosipovitch
University of Miami Miller School of Medicine, Miami, USA

Kilian Eyerich
University of Freiburg, Germany

Delphine Staumont-Sallé
University of Lille, Lille, France

Mona Shahriari
Yale University School of Medicine, New Haven, USA

Gaia Gallo
Eli Lilly and Company, Indianapolis, USA

Eric Wolf
Eli Lilly and Company, Indianapolis, USA

Evangeline Pierce
Eli Lilly and Company, Indianapolis, USA

Chunyuan Liu
TigerMed Inc, Somerset, USA

Jinglin Zhong
IQVIA, Durham, USA

Helena Agell
Almirall, S.A., Barcelona, Spain

Marjolein de Bruin-Weller
University Medical Center Utrecht, The Netherlands

Keywords

Lebrikizumab, EASI, itch, atopic dermatitis, rapid response

References

1. Okragly AJ, et al. DermatolTher (Heidelb). 2023;13:1535-1547.​

2. Ratnarajah K, et al. J Cutan Med Surg. 2021;25:315-328.​

3. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.​

4. Blauvelt A, et al. Br J Dermatol. 2023;188:740-748. ​

5. Simpson EL, et al. JAMA Dermatol. 2023;159:182-191​

6. Yosipovitch G, et al. Br J Dermatol. 2019;181:761-769.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.279

Article Details

How to Cite
[1]
Simpson, E. , Yosipovitch, G. , Eyerich, K. , Staumont-Sallé, D. , Shahriari, M. , Gallo, G. , Wolf, E. , Pierce, E. , Liu, C. , Zhong, J. , Agell, H. and de Bruin-Weller, M. 2023. Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s279. DOI:https://doi.org/10.25251/skin.7.supp.279.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 > >>